Use of pramipexole in the treatment of restless legs syndrome

Details Use of pramipexole in the treatment of restless legs syndrome Use of pramipexole in the treatment of restless legs syndrome

1999-10-27

2001-02-27

Spivack, Phyllis G. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

06194445

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to the use of pramipexole or 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazole or the (−)-enantiomers thereof, and the pharmacologically acceptable salts thereof, in the treatment of restless leg syndrome.
BACKGROUND OF THE INVENTION
Restless leg syndrome (RLS) is a neurosensorimotor disorder with parestethesias, sleep disturbances and, in most cases, periodic limb movements of sleep (PLMS).
Pramipexole is a dopamine-D
3
/D
2
agonist the synthesis of which is described in European Patent 186 087 and its counterpart, U.S. Pat. No. 4,886,812. It is known primarily for the treatment of schizophrenia and Parkinson's disease. It is known from German patent application DE 38 43 227 that pramipexole lowers the plasma level of prolactin. Also, this European patent application discloses the use of pramipexole in the treatment of drug dependency. Further, it is known from German patent application DE 39 33 738 that pramipexole can be used to decrease abnormal high levels of thyroid stimulating hormone (TSH). U.S. Pat. No. 5,112,842 discloses the transdermal administration of the compounds and transdermal systems containing these active compounds. The WO patent application PCT/EP 93/03389 describes pramipexole as an antidepressant agent, while the PCT application PCT/US95/15618 discloses the neuroprotective effects of pramipexole.
Surprisingly and unexpectedly, it has been found that pramipexole and the pharmacologically acceptable salts thereof can be used in the treatment of restless leg syndrome.
SUMMARY OF THE INVENTION
The present invention particularly provides a method for treatment of restless legs syndrome in a patient suffering from or susceptible to such condition comprising the administration of an effective amount of pramipexole. By pramipexole is meant 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole, its (−)-enantiomer thereof, and pharmacologically acceptable salts thereof especially (−)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole dihydrohloride (H
2
O).
2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole, particularly the (−)-enantiomer thereof, and the pharmacologically acceptable acid addition salts thereof can be given for treating RSL. The form of conventional galenic preparations consist essentially of an inert pharmaceutical carrier and an effective dose of the active substance; e.g., plain or coated tablets, capsules, lozenges, powders, solutions, suspensions, emulsions, syrups, suppositories, etc.
Preferred are tablets comprising 0.88 (0.125), 0.18 (0.25), 0.7 (1.0), 088 (1.25) and 1.1 (1.5) mg of Pramipexole base (mg Pramipexole 2HCl), respectively, and further comprising mannitol, maize starch, colloidal silica, polividone and magnesium stearate as excipients.
The effective dose range is 0.001 to 10.0 mg/day and patient, preferred between 0.001 and 6, more preferred between 0.01 to 6 and especially preferred between 0.75 and 4.5 mg/day and patient p.o. In addition to being administered by oral or intravenous route pramipexole may also be administered transdermally or by inhalation.
Dosages should be increased gradually from a starting dose of about 0.264 mg of base per day and then increased every 5-7 days. Providing patients do not experience intolerable side effects, the dosage should be titrated to achieve a maximal therapeutic effect.


REFERENCES:
patent: 5112842 (1992-05-01), Zierenberg et al.
patent: 3933738 (1989-10-01), None
patent: 3843227 (1990-07-01), None
patent: 0186087 (1985-12-01), None
patent: 94/13287 (1994-06-01), None
patent: 96/18395 (1996-06-01), None
patent: WO98/31362 (1998-07-01), None
JE Ahlskog, et al., “Adjunctive Cabergoline Therapy of Parkinson's Disease: Comparison with Placebo and Assessment of Dose Response and Duration of Effect,” Clin. Neuropharmacol, 1996; 19:202-212.
S Akpinar, “Restless Legs Syndrome Treatment with Dopaminergic Drugs,” Clinical Neuropharmacology, 1987; 10:69-79.
RP Allen, et al., “Augmentation of the Restless Legs Syndrome with Carbidopa/Levodopa” Sleep, 1996; 19(3):205-13.
Anonymous Author, “My Doctor Prescribed Sinemet for my Restless Legs and it was a Catastrophe,” Johns Hopkins Medical Letter, Health After 50, 1998; 10 (12) 8.
Anonymous Author, “Restless Legs Syndrome Often Not Recognized, May be Misdiagnosed,” Geriatrics, 1998; 53(2): 101.
PM Becker, et al., “Dopaminergic Agents in Restless Legs Syndrome and Periodic Limb Movements of Sleep: Response and Complications of Extended Treatment in 49 Cases,” 1993; Sleep, 16(8); pp. 713-716.
D Boghen, et. al., “The Treatment of Restless legs Syndrome with Clonazepam: A Prospective Controlled Study,” Can J Neurol Sci, 1986; 13:245-247.
B Bornstein, “Restless Legs,” Psychiat Neurol, 1961; 141:165-201.1.
C Brodeur, et. al., “Treatment of RLS and PMS with L-dopa: A Double-blind Controlled Study,” Neurology, 1988; 35:1845-1848.
N Callaghan, “Restless Legs Syndrome in uremic Neuropathy,” Neurology, 1966; 16:359-361.
RM Coleman, “Periodic Movements in Sleep (Nocturnal Myoclonus) and Restless Legs Syndrome.” In: Guilleminault C, (ed) Sleeping and Walking Disorders: Indications and Techniques, 1982; Menlo Park: Addison Wesley, 265-295.
V Collado-Seidel, et al., “A Controlled Study of Additional sr-L-dopa in L-dopa-Responsive Restless Legs Syndrome with Late-Night Symptoms,” Neurology, 1999; 52:285-290.
CJ Earley, et al., “Pergolide and Carbidopa/Levodopa Treatment of the Restless Legs Syndrome and Periodic Leg Movements in Sleep in a Consecutive Series of Patients,” Sleep 1996; 19(10):801-10.
KA Ekbom, “Restless Legs,” Acta Medica Scandinavica, 1945; suppl. 158: 1-123.
KA Ekbom, “Restless Legs Syndrome,” Neurology, 1960; 10:868-873.
RG Fariello, “Pharmocodynamic and Pharmacokinetic Features of Carbergoline,” Drugs, 1997; 55:S2, 10-16.
A Feigen, “Restless Legs Syndrome,” JAMA, 1995; 274 (15) 1191-2.
B Frankel, “Restless Legs Syndrome,” JAMA, 1974; 230:1302-1303.
LI Golbe, “Pregnancy and Movement Disorders,” Neurologic Clinics, 1994; 12/3 (497-508).
C Gorman, et al., “Symptoms of Restless Legs,” Arch Intern Med, 1965; 115:155-60.
C Guilleminault, et al., “Dopaminergic Treatment of Restless Legs and Rebound Phenomenon,” Neurology, 1993; 43(2):445.
D Harriman, et al., “Ekbom's Syndrome and Burning Paraesthesiae,” Brain, 1970; 93:393-406.
EM Heiman, et al., “Lithium-aggravated Nocturnal Myoclonus and Restless Legs Syndrome [letter],” American Journal of Psychiatry, 1986; 143:1191-1192.
F Heinze, et al., “Restless Legs and Orthostatic Hypotension in Primary Amyloidosis,” Arch Neurol, 1967; 16:497-500.
W Hening, et al., “The Cortical Premovement Potentials in RLS Jerks,” Sleep Res, 1991; 20:255.
WA Hening, et. al., “Dyskinesias while awake and periodic movements in Sleep in Restless Legs Syndrome: Treatment with Opioids,” Neurology; 1986; 36:1363-1366.
S Iannacone, et al., “Evidence of Peripheral Axonal Neuropathy in Primary Restless Legs Syndrome,” Movement Disorders, 1995; 10:2-9.
J Jorgensen, et al., “Restless Legs Syndrome,”—Abstract, Ugeskrift for Laeger, 1989; 151 (11) 670-1.
PW Kaplan, et al., “A Double-Blind, Placebo-Controlled Study of the Treatment of Periodic Limb Movements in Sleep using Carbidopal/Levodopa and Propoxyphene,” Sleep, 1993; 16 (8) 717-23.
S Kotagal, et al., “Nocturnal Myoclonus—A Sleep Disturbance in Children with Leukemia,” Annal of Neurology, 1984; 16:392.
E Lugaresi, et al., “Nocturnal Myoclonus and Restless Legs Syndrome,” In: S Fahn et al. (eds), Advances in Neurology, 1986; vol. 43: Myoclonus, New York: Raven Press; 295-307.
MW Mahowald, et al., “Parasomnias Including the Restless Legs Syndrome,” Clinics in Chest Medicine, 1998; 19/1 (183-202).
P Martinelli, et al., “Nocturnal Myoclonus, Restless Legs Syndrome, and Abnormal Electrophysiological Findings,” Ann Neurol, 1987; 21:515.
WB Matthews, “Iron Deficiency and Restless Legs,” Br Med J, 1976; 1-898.
M Miyagi, et al., “Dopamine Receptor Affinities in vitro and Steriotypic Activities in vivo of Cabergoline in Rats,” Biol. Pharm. Bull., 1996; 19L 1210-1213.
H

Affiliated with

Also associated with

Rating

Use of pramipexole in the treatment of restless legs syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of pramipexole in the treatment of restless legs syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of pramipexole in the treatment of restless legs syndrome will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2590656